|
27 Jun 2022 |
Ipsen to acquire Epizyme, expanding its portfolio in oncology
|
|
24 Jun 2022 |
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
|
|
23 Jun 2022 |
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT
|
|
22 Jun 2022 |
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
|
|
16 Jun 2022 |
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
|
|
15 Jun 2022 |
Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer
|
|
15 Jun 2022 |
Boehringer Ingelheim signs Option to Acquire Trutino Biosciences
|
|
14 Jun 2022 |
D. E. Shaw Research Licenses First-in-Class Therapeutic for Immunological Diseases to Lilly
|
|
14 Jun 2022 |
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
|
|
13 Jun 2022 |
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
|
|
10 Jun 2022 |
Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
|
|
08 Jun 2022 |
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
|
|
06 Jun 2022 |
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
|
|
03 Jun 2022 |
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
|
|
03 Jun 2022 |
Boehringer Ingelheim enters global licensing agreement to develop and commercialize innovative antibodies from A*STAR for targeted cancer therapies
|
|
03 Jun 2022 |
Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
|
|
02 Jun 2022 |
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
|
|
02 Jun 2022 |
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
|
|
01 Jun 2022 |
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
|
|
31 May 2022 |
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
|
|
24 May 2022 |
KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
|
|
23 May 2022 |
Innoviva to Acquire Entasis Therapeutics
|
|
20 May 2022 |
Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review
|
|
19 May 2022 |
Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans
|
|
19 May 2022 |
Almirall and Evotec enter into a multi-target alliance in Medical Dermatology
|
